FDA Publicly Identifying Companies Who May Be Delaying Generics

List posted last week on FDA website

The U.S. Food and Drug Administration (FDA) has followed through on its promise to publicly name companies it says may be gaming drug laws to block generic competition.

The unprecedented move is part of the Trump administration’s effort to bring down the prices of pharmaceuticals. The list was posted on the FDA’s website last Thursday, and includes dozens of companies—both generic and brand-name organizations represented—the agency said appear to have refused to give up samples of their product to generic companies seeking to make copies.

Commissioner Scott Gottlieb, MD, said the agency has received over 150 pleas for help from generic drugmakers who have been unable to get samples from companies.

“We’re also notifying the Federal Trade Commission (FTC) — the agency responsible for addressing anticompetitive business practices — about these inquiries,” he said.

The complete FDA list is available on the organization’s website.

SOURCE: Medscape

About The Author

Each year more than 350,000 professionals advance their career with Elite Learning.